Skip to main content
SpringerLink
Log in

Ceritinib

Development of resistance in colorectal adenocarcinoma: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Yakirevich E, et al. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clinical cancer research: an official journal of the American Association for Cancer Research 22: 3831-3840, No. 15, Aug 2016. Available from: URL: http://doi.org/10.1158/1078-0432.CCR-15-3000 - USA

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ceritinib. Reactions Weekly 1695, 99 (2018). https://doi.org/10.1007/s40278-018-43926-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-43926-0

Search

Navigation